|
Carol A. Ziomek is a founding member of GTC Biotherapeutics. Dr. Ziomek manages the technical aspects of product development for recombinant antithrombin III from gene construct to final product production and leads the multi-disciplinary team that is developing the rhATIII viral and pathogen safety strategies. She also is a member of the technology evaluation team assessing new technologies for improved efficiency of the transgenic production process.
Dr. Ziomek has over 20 years of transgenic production experience including several years with Genzyme Corporation as head of the transgenic embryology department and as Staff Scientist at the Worcester Foundation for Experimental Biology.
Dr. Ziomek received a Ph.D. in Biology from Johns Hopkins University performed her post-doctorate at the University of Cambridge England and holds a Bachelor's degree in Chemistry from Wilkes College Pennsylvania. | 